40 articles, transcripts, and reports
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023. Total revenue declined 3%…
Biogen, Inc. (NASDAQ: BIIB) Q4 2022 earnings call dated Feb. 15, 2023 Corporate Participants: Michael Hencke — Head of Investor Relations Christopher A. Viehbacher — President and Chief Executive…
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2022 earnings results today. Total revenue fell 7% year-over-year to $2.54 billion. Net income attributable to Biogen Inc.…
Biogen Inc. (NASDAQ: BIIB) Q3 2022 earnings call dated Oct. 25, 2022 Corporate Participants: Mike Hencke — Head, Investor Relations Michel Vounatsos — Chief Executive Officer Priya Singhal — Head, Global…
Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in revenues and adjusted…
Biogen Inc. (NASDAQ: BIIB) Q2 2022 earnings call dated Jul. 20, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations. Michel Vounatsos — Chief Executive Officer Priya Singhal — Interim…
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable to Biogen Inc.…
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the ambitious launch of…
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable to Biogen Inc.…
Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Priya Singhal — Head…
